Skip to content

The Effect of Tegliadine Fumarate on Postoperative Nausea and Vomiting and Analgesia in Patients Undergoing Gynecological Laparoscopic Surgery

A Randomized Controlled Trial of Tegliadine Fumarate for Preventing Postoperative Nausea and Vomiting and Improving Analgesic Efficacy in Patients Undergoing Gynecological Laparoscopic Surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113795
Enrollment
Unknown
Registered
2025-12-03
Start date
2025-12-20
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

Tegliadine Fumarate Group:0.02 mg/kg Tegliadine administered intravenously during induction, and 0.01 mg/kg Tegliadine administered intravenously 10 minutes before skin closure.
Sufentanil Citrate Group:0.02 µg/kg Sufentanil administered intravenously during induction, and 0.01 µg/kg Sufentanil administered intravenously 10 minutes before skin closure

Sponsors

Department of Anesthesiology, Taizhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, female patients; 2. ASA physical status classification ?–?; 3. Patients identified as being at high risk of postoperative vomiting (preoperative Apfel score = 3); 4. Body Mass Index (BMI) 18.5-30 kg/m²; 5. Hospital stay > 48 hours; 6. Surgical duration < 2 hours.

Exclusion criteria

Exclusion criteria: 1. Inability to communicate preoperatively due to cognitive impairment or language barrier; ?2. Preoperative history of chronic pain or opioid abuse; ?3. Patients with preoperative gastrointestinal or other related diseases prone to causing vomiting; ?4. History of drug use and/or alcohol abuse within the past 3 months; ?5. Patients who are expected to be unable to assess pain intensity postoperatively or to be transferred to the ICU; 6. Patients with expected intraoperative blood loss > 1000 ml or other serious complications during surgery; ?7. Severe systemic diseases involving the heart, lungs, liver, kidneys, etc.; ?8. Patients with central nervous system diseases or mental system disorders.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale Score for Postoperative Nausea and Vomiting ;

Secondary

MeasureTime frame
Postoperative Nausea and Vomiting Incidence;Numerical Rating Scale Pain Score;Recovery Room Stay Duration;Ramsay Sedation Scale Score;Quality of Recovery-15 Scale Score;Postoperative Satisfaction Score;Postoperative Adverse Reactions;

Countries

China

Contacts

Public ContactWang Wenwei

Department of Anesthesiology, Taizhou First People's Hospital

www2229@163.com+86 151 0586 8192

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026